Our group developed a new generation of chip-based small-scale devices for continuous purification of chemicals and nanoparticles, based on the interactions of analyte with multiple types of driving forces in an electro-fluid-dynamic (EFD) system. One series of the purification devices has the electric field in parallel with the fluid flow direction (E?F), while the other series has two orthogonal driving force fields (E?F).
Preterm neonates ill-adapted to the extra uterine environment are prone to increased inflammation in multiple organs and the proinflammatory interleukine IL-1b has been closely implicated in brain injury associated with preterm birth (PTB). Notably, PTB survivors have a greater propensity to develop ischemic brain lesions long after birth. Here, we hypothesize that the neural vasculature of premature infants becomes irresponsive to hypoxic-ischemic stress.
Pertussis, also known as whooping cough, is a contagious bacterial disease that targets cells in the human respiratory tract. Whooping cough is an airborne disease that causes coughing fits, difficulty breathing and potentially death. Although it can be life threatening, the disease is preventable with proper immunization. Pertactin is a commonly used protein derived from the bacterial species, B. pertussis, used in the production of the vaccine against the disease.
This collaboration between pharmaceutical company NuvoBio and a Research Team led from the University of Windsor and working with Dalhousie and the University of Western Ontario seeks to develop a new vaccine for lung cancer. The students and postdoctoral fellows will be making new types of molecules and investigating some underlying questions about how we formulate vaccines, as well as preparing these promising compounds and studying their safety an efficiency in preventing and eliminating lung cancers.
One aspect of modern drug development involves understanding how enzymes function in terms of the progress of certain diseases in humans. This MITACS project involves the synthesis of small-molecule labels that can bind to a specific enzyme of interest, so as to better understand the mode of action of this enzyme as related to the progress of cancer. This work will involve the preparation of organic molecules possessing appropriate structural features that will enable selective and irreversible binding to the desired enzyme.
Alzheimers disease (AD) is an age-related neurodegenerative disease affecting more than >45 million individuals worldwide with numbers expected to reach >135 million by 2050. The multifactorial nature of AD hinders the development of therapeutic treatments and, as such, several drug candidates have failed in clinical trials. Polyphenolic compounds have the ability to reach the brain and target the multifactorial aspects of AD.
A novel technology for delivery of biologically active compounds found in hemp oil is being developed. This novel technology significantly reduces the health risks associated with traditional administration of Cannabis products (e.g., smoking and THC-related intoxication) The proposed project, in collaboration with a federally-licensed facility for cannabinoid analysis, Abattis Bioceuticals, engages into the development of two different platforms for encapsulation of hemp oil using nanoemulsion and nanolipid carrier technologies.
Castration-resistant prostate cancer is a late stage disease and many people die of it due to lack of effective therapeutic drugs. In the current project, we propose to develop new therapeutic drug a to specifically target CRPCs common weak points, which are MCT4 and eIF4E genes proteint products that play very important roles in regulation of cancer cells energetic and protein translation pathways. The project aims to develop an antibody drug, an small molecule chemical drug and a nanoparticle drug to target MCT4 membrane protein and eIF4E transcription factor protein.
Genacol Canada Corporation Inc. manufactures a bovine-sourced hydrolyzed collagen supplement (Genacol® Original Formula), which has shown efficacy in two separate clinical trials for reducing joint pain. Following digestion, hydrolyzed collagen yields amino acids and peptides that can lead to the health promoting properties of the supplement. However, the specific identity and mechanisms of action of the peptide and amino acids produced from the digestion of the Genacol collagen hydrolysate that support joint health is unclear.
The purpose of this project will be to develop a flexible and statistically sound methodology for leveraging BPIs database of current and historical publicly available coverage information to model coverage trends in the U.S. health insurance industry. The project will also include the development of an R Markdown template for future predictive analytics reports. The templates and methodologies developed for this project will be integrated into BPI, Inc.'s custom consulting division.